• 
WHEN
7, 8, 9 and 10 
May 2024

ISI News

Inscrições presenciais encerradas!

O 7th ISI já é um sucesso!

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Donec a mauris elementum orci gravida laoreet. Sed vel magna neque. Donec vulputate libero ut erat blandit dignissim. Cras ut malesuada quam. Nulla non congue lacus, non facilisis sapien. Maecenas at neque sit amet turpis bibendum lobortis sit amet et massa. Phasellus laoreet elit eget sollicitudin convallis. Nulla finibus diam malesuada felis lacinia, quis placerat mauris feugiat. Mauris ut justo posuere nunc eleifend lobortis. Aenean hendrerit diam eu dolor rhoncus, sed pulvinar nisl pretium. Nam aliquam metus lorem, eget interdum ipsum aliquam et. Proin laoreet tellus et odio egestas, vel laoreet sapien posuere. Sed dapibus, tortor quis convallis vestibulum, arcu est hendrerit tortor, id sollicitudin magna tortor at dolor. Pellentesque at velit sem. Phasellus et felis ultrices, malesuada magna nec, auctor metus.

O Evento

A realização da sétima edição do International Symposium on Immunobiologicals (ISI) terá como objetivos principais o fomento à inovação, a geração de conhecimento de ponta e o networking entre especialistas para acelerar o desenvolvimento de soluções em biotecnologia para os problemas de saúde pública. Na edição de 2021, o ISI ganhou um formato digital, que permitiu a participação à distância nas palestras, mesas redondas, minicursos e workshops, que foram transmitidos em tempo real da plataforma virtual especialmente concebida para responder a esta nova realidade imposta pela pandemia. Já em 2022 o ISI se tornou um evento híbrido, que contou também com sessões presenciais seguindo todos os protocolos de segurança, uma vez que o estágio da pandemia possibilitou a volta de algum contato físico. Porém em 2023, o evento passa a ser prioritariamente presencial, com atividades participativas, para estimular a troca de conhecimentos e a interação entre os participantes.

Seja presencialmente ou através da plataforma virtual, o ISI é o espaço ideal para buscar conhecimento de ponta na área de biotecnologia no mundo, conhecer pesquisadores e cientistas de destaque, compartilhar o que se está fazendo e ouvir o feedback de seus pares na área de pôsteres, além de obter atualizações sobre temas importantes para as carreiras da área e ficar sabendo o que as empresas de destaque no mercado estão oferecendo.

Inscrições

Participe do 7º ISI!

A participação no 7º ISI é gratuita e aberta a todos os profissionais ou estudantes, além de pesquisadores da área de imunobiológicos e afins, provenientes de instituições de produção e/ou desenvolvimento tecnológico de vacinas, biofármacos ou reativos para diagnóstico, bem como envolvidos na área de saúde pública. Também se destinam a empreendedores, startups, investidores e agências de fomento. A inscrição é gratuita tanto para brasileiros quanto para estrangeiros, desde que se enquadrem nos requisitos acima mencionados.

Inscreva-se!

Exposição de Pôsteres

Estão abertas as submissões de pôsteres para o 7º International Symposium on Immunobiologicals

Não deixe de apresentar o seu trabalho no 7º International Symposium on Immunobiologicals. 

As submissões de pôsteres estarão abertas até 7 de março. 

Trabalhos inéditos sobre vacinas, kits para diagnóstico e biofármacos, gestão ou outros temas relacionados podem ser enviados até o dia 7 de março. Não há limite para o número de resumos a serem submetidos por autor. Caso selecionados, os trabalhos participarão da exposição de pôsteres, que em 2023 volta a ser presencial durante o evento, aumentando a visibilidade e as possibilidades de interação com os pares. Mas continua tendo também sua divulgação virtual, com espaço para o resumo, vídeo e o pôster, além da possibilidade de chat com os participantes e videoconferências. Não deixe de submeter o seu trabalho!

Submeta seu resumo!

Confira as edições anteriores!

Quer saber como foi o International Symposium on Immunobiologicals (ISI) e ver um pouco do que já aconteceu?

Confira!

Programação do 7º ISI 2023

Confira o que está previsto de acontecer no evento de 2023 e se planeje para participar.

Download da programação

  • May 07




  • Digital Transformation in the Biopharmaceutical Industry

    Where
    On-site: Capacity Building Auditorium Centro Administrativo Vinicius Fonseca



  • Artificial Intelligence and diagnostic tools: Challenges for application in the Unified Health System (SUS)

    Where
    Online



  • Exploring Advanced Therapies: From conception to clinical practice

    Where
    On-site: Capacity Building – Auditorium Centro Administrativo Vinicius Fonseca



  • Adjuvants for human use and their different applications

    Where
    Online

  • Upon registration here.
    Where
    Technological Vaccine Complex and Castelo Mourisco

  • Upon registration here.
    Where
    Technological Vaccine Complex and Castelo Mourisco

  • Guests of the Bio-Manguinhos’ Board
    Where
    Auditorium 5th floor – Centro Administrativo Vinicius Fonseca

  • May 08


  • Credentials

    Science talks 1: Opening of the poster exhibition

  • Oral presentation 2: ORT-01 – Investigation of recombinant SARS-CoV-2 nucleocapsid protein thermal properties and its nucleic acid interaction – Luanna Elisa Liebscher Vidal

  • Chair: Julio Croda, Fiocruz*



    Presentations:
    Emergency preparedness and response in Brazil
    Ethel Maciel – MoH/SVS

    The impact of COVID-19 in Africa and lessons for the future
    Christopher Gill, Bill & Melinda Gates Foundation*

    New accelerated technologies for diagnostics, vaccines and treatmens
    Rino Rappuoli, Biotecnopolo di Siena Foundation
    Kits-diagnóstico
    Vacinas

  • Coffee break

    Poster pitch 1: VAC-06 – Immunita-001: Cross-sectional study of immunogenicity, safety and infection by SARS-CoV-2 in adults vaccinated with the inactivated virus vaccine (CoronaVac) in a two-dose protocol and heterologous booster doses
    Sarah Vieira Contin Gomes

    Poster pitch 2: VAC-07 – Cellular response in severe adverse events after COVID-19 vaccination
    Felipe Soares Coelho

    Poster pitch 3: ORT-05 – Spatial-temporal patterns in biologic prescriptions for inflammatory bowel diseases in the public healthcare system in Brazil
    Caroline Tianeze de Castro

    Poster pitch 4: ORT-08 – Correlation between detection of viral gastroenteritis and climatic factors in the Northwest Am.azon región
    Nathalia Alves Araujo de Almeida


  • Chair:
    Mauricio Zuma, Bio-Manguinhos / Fiocruz*

    Speaker:
    Rajinder Suri / DCVMN*

    Discussants:
    Adriansjah Azhari, Biofarma*; Tiago Rocca, Butantan*; Venkatraman Sivaramakrishnan, BharatBiotech*; Rachel Park, EuBiologics*; Sunil Gairola, Serum Institute of India*; Andrew Wong, Walwax*; Fernando Lobos, Sinergium Biotech*
    Vacinas

  • Poster pitch 5: BIO-06 – Evaluation of sporicidal activity of 2%peracetic acid against filamentous fungus strains for contamination control strategy in a pharmaceutical industry
    Amanda Silva Costa

    Poster pitch 6: ORT-07 – FUT2 gene profile of children with acute gastroenteritis, HBGA non-secretors living in the Northwest Amazon region, and association with rotavirus A and norovirus infection
    Mauro França da Silva

    Poster pitch 7: ORT-02 – Evaluation of Fourier-Transform Infrared Spectroscopy as a rapid method to type Stenotrophomonas maltophilia strains isolated from pharmaceutical industry
    Paula Araujo de Souza

    Poster pitch 8: ORT-15 – Comparison between different VITEK® 2 and MALDI Biotyper® for the identification of Bacillus subtilis group
    Laís dos Santos Oliveira

    Poster pitch 9: ORT-10 – Antimicrobial resistance profile and aggregation capacity evaluation of Burkholderia cepacia complex strains isolated in a pharmaceutical facility
    Francisca Letícia de Sousa Sales

    Poster pitch 10: MAN-03 – Interchangeability of Adalimumab originator and biosimilars in Brazil: real-life evidence opportunity
    Mariana Jorge de Queiroz

    Poster pitch 11: MAN-02 – Regulatory Intelligence (RI) applied to the registration and post-variation of Bio-Manguinhos vaccines and biopharmaceuticals
    Celina Vieira da Cunha Guedes Alvarenga

    Poster pitch 12: MAN-04 – Implementation of the Lead Time methodology for managing the analysis of pharmaceutical inputs in Quality Control
    Ana Paula Roque da Silva


  • Main aspects of production and quality of hexavalent vaccines and experience of implementing acellular vaccines in public programs in Latin America

    Chair: Dr José Cássio de Moraes, São Paulo Medical School


    Presentations:
    Main aspects of acellular Vaccines´ Production and Quality
    Dr Cesar Mascareñas, Sanofi

    Experience of acellular vaccines` introduction in public programs in Latin America
    Dra María Luisa Ávila Aguero, University of Costa Rica


  • Chair:
    Carlos Gadelha, SECTICS / Brazilian MoH *


    Discussants:
    Artur Couto, Bio-Manguinhos/Fiocruz*; Esper Georges Kallás, Butantan*; Jorge Mendonça, ALFOB*; Odilon José da Costa Filho, Abifina
    Gestão

  • Oral presentation 4: MAN-01 – Building A Healthy Future: Health Needs And Technological Horizons In Immunobiologicals – Julianna do Nascimento e Silva Varela

  • Coral da Fiocruz

    Chair:
    Akira Homma, Bio-Manguinhos / Fiocruz*


    Authorities:
    – Carlos Gadelha, SECTICS / Brazilian MoH
    – Mario Santos Moreira, Fiocruz*
    – Tedros Adhanom Ghebreyesus, WHO*
    – Jarbas Barbosa* and Socorro Gross, PAHO*
    – BMGF
    – GAVI
    – FGV
    – Maurício Zuma, Bio-Manguinhos / Fiocruz*



  • Poster pitch 13: IVD-04 – Design of a new optimized VLP as a positive control of molecular diagnostic kits
    Alexandre Rodrigues Calazans

    Poster pitch 14: IVD-06 – Establishing proof-of-concept for multiplex lateral flow assay to congenital and perinatal infections
    Ana Paula dos Santos

    Poster pitch 15: IVD-15 – Development of a new multiplex platform for detection and screening for virus-caused exanthematic diseases
    Pedro Henrique Cardoso

    Poster pitch 16: IVD-14 – Extending the Shelf-Life of Protein A Gold conjugate for Rapid Syphilis Testing: A Comprehensive Stability Analysis
    Giselle Santana de Oliveira

    Poster pitch 17: IVD-05 – Development and Optimization of Immunological Assay for Evaluation of FITC Immunoconjugates
    Marcelle Mello

    Poster pitch 18: IVD-10 – Assessment of coinfection by Ehrlichia canis and Babesia canis in a Canine Visceral Leishmaniasis serological panel
    Carlos Renato Calvet da Silva



    Book launch and autograph session – Biotecnologia



  • May 09


  • Welcome coffee


    Poster pitch 19: BIO-16 – Sustainable compendial grade GMP detergent substitutes for Triton™ X-100 in bioprocessing applications
    Letícia Paifer Marques

    Poster pitch 20: BIO-11 – Characterization of anti-PD-1 biosimilar monoclonal antibody candidates using established methodologies
    Thayane Aparecida Alves de Araujo

    Poster pitch 21: BIO-09 – Structural modeling of two anti-Acinetobacter baumannii monoclonal antibodies and the target surface protein
    Laianne Dias Inácio

    Poster pitch 22: IVD-08 – Evaluation of molecular assays for the detection of respiratory viruses with a view to structuring the national Wastewater-based epidemiology program
    Lara Corrêa Umpierre Henriques


  • Oral presentation 6: IVD-03 – Assessment of the activity of the anti-PBP2a monoclonal antibody from methicillin-resistant Staphylococcus aureus (MRSA) against Enterococcus spp. – Julia Hamam de Lucca Teixeira


  • Foundations for translational research and partnerships to accelerate the technological development of biologic products


    Chair:
    Leda Castilho, UFRJ*


    Presentations:
    Brazilian National Center for Research in Energy and Materials (CNPEM): cutting-edge Science to tackle Global Health Challenges
    Maria Augusta Arruda – CNPEM/LMBIO*

    Prototype plant
    Elaine Teles, Bio-Manguinhos / Fiocruz*

    Infrastructure to accelerate Innovation in vacines
    Raches Ella, Bharat Biotec*

    Biofármacos
    Vacinas

  • Coffee break


    Poster pitch 23: ORT-09 – Laboratory diagnosis of human parvovirus B19 infection in acute febrile illnesses in a malaria-endemic area on the border of Brazil and French Guiana
    Ester dos Santos Motta

    Poster pitch 24: VAC-10 – Peptides for a polyeptide anti-leishmanial vaccine
    Prisciliana Jesus de Oliveira

    Poster pitch 25: VAC-05 – Design of a global multiepitope orthohantavirus vaccine: An Immunoinformatics Approach
    Silvia da Silva Fontes
    Poster pitch 26: ORT-04 – Exploring the Interplay of CLEC5A and Zika Virus: In Silico and In Vitro Investigations
    Ryann de Souza Nascimento


  • Chair:
    Ricardo de Godoi, Bio-Manguinhos / Fiocruz*


    Presentations:
    Next-generation virus production: from clone, to AMBR, to perfusion and very high virus yield
    Yvonne Genzel, Max-Planck-Institute, Germany*

    Vaccines for a safer world – the pitfalls in the development of vaccines for neglected diseases
    Hayato Urabe, GHIT*

    Managing innovation in human health biotechnology startups in Brazil: Evidence and lessons learned
    Paulo Negreiros Figueiredo, FGV*
    Vacinas

  • Lumit™️: Uma plataforma para o desenvolvimento de métodos rápidos e sensíveis de detecção de analitos
    Juliano Alves, Promega Corporation*

  • Lunch box


    Poster pitch 27: ORT-06 – Human papillomavirus DNA versus Pap smear screening test in women living with human immunodeficiency virus
    Milena Siqueira Pereira

    Poster pitch 28: VAC-09 – Human Papillomavirus vaccination safety: signal detection from vaccine pharmacovigilance, Brazil, 2013-2022
    Mateus de Paula von Glehn

    Poster pitch 29: ORT-18 – Molecular epidemiology of Human Papillomavirus
    Rachel Siqueira de Queiroz Simoes

    Poster pitch 30: BIO-07 – Upstream optimization of recombinant L-asparaginase production in E. coli for the treatment of Acute Lymphoblastic Leukemia
    Gabriela de Assis Ferreira

    Poster pitch 31: ORT-11 – Generation of allogeneic 19BBz CAR-T using CRISPR
    Eduardo Mannarino Correia

    Poster pitch 32: BIO-08 – Optimizing sample preparation and nLC-MS/MS for mAB characterization
    Rodrigo Soares Caldeira Brant

    Poster pitch 33: BIO-12 – Obtainment and characterization of TIM-3_ECD-FC in HEK293-T cells as an antigen for the selection of antibodies for antitumor immunotherapy
    Marielly Câmara Rocha

    Poster pitch 34: BIO-03 – Evaluation of the affinity between single-chain M971 antibody fragments and the CD22 membrane glycoprotein for a CAR-T cell
    Alice Soares de Queiroz


  • Chair:
    Gustavo Mendes, Butantan*


    Presentations:
    Korean approach sudy case
    Christiane Gerke, IVI*

    China approach study case
    George Fu Gao, Chinese Academy of Sciences*
    Biofármacos
    Vacinas

  • Oral presentation 8: BIO-01 – Efficient large-scale point-of-care production of affordable Anti-CD19 CAR-T cells for leukemia immunotherapy – Leonardo Ribeiro Batista Silva

  • Chair:
    Antonio Carlos Campos de Carvalho, Fiocruz*


    Presentations:
    AAV – based vectors as a platform for treating diseases
    James Wilson, UPENN*

    Lentiviral vector-based solutions to treat human diseases
    Boro Dropulic, Caring Cross*

    Gene therapy- based approaches to treat patients in SUS
    Martín Bonamino, INCa/Fiocruz*
    Biofármacos


  • May 10


  • Welcome coffee


    Poster pitch 35: VAC-08 – Downstream establishment of the chimeric live-attenuated zika virus vaccine
    Stephanie Almeida da Silva

    Poster pitch 36: IVD-07 – Development and standardization of the PAN–FLAVI assay for the detection of flaviviruses with epidemiological importance in Brazil
    Anielly Ferreira de Brito

    Poster pitch 37: IVD-09 – Adaptation and evaluation of point-of-care tests for infectious diseases in the telediagnosis system in Pernambuco – UBS
    Wagner José Tenório dos Santos

    Poster pitch 38: IVD-12 – Kit Molecular ZC_D Tipagem Bio-Manguinhos: arbovirus discriminatory assay in CSF simples
    Beatriz Vasconcello de Souza Barreto


  • Oral presentation 10: VAC-01 – Type I interferon innate errors causing severe adverse events following yellow fever vaccination: a family-based case study – Tamiris Azamor da Costa Barros

  • Chair:
    Margareth Dalcolmo, Fiocruz*


    Presentations:
    Vaccination policy against Dengue
    Eder Gatti, CGPNI – MoH*

    Wolbachia method: a powerful strategy for controlling arboviruses
    Karlos Diogo Chalegre, Fiocruz*

    Clinical trials of a Dengue vaccine
    Fernanda Castro Boulos, Butantan*
    Gestão
    Vacinas

  • Coffee break


    Poster pitch 39: IVD-13 – Comparing Blue and Red Gold Nanoparticles in Protein A Bioconjugation for Rapid Diagnostic Tests
    Gabriel Mustafá Misirli

    Poster pitch 40: ORT-17 – Continuous Flow Synthesis of Monodisperse Gold Nanoparticles
    Waldemir de Castro Silveira

    Poster pitch 41: VAC-04 – Assessing mRNA Integrity using Capillary Electrophoresis: Insights into Scientific Parameters
    Raysa Silva de Souza

    Poster pitch 42: ORT-13 – Identification of isolates from an immunobiological industry: comparison between VITEK®2, MALDI-TOF MS and 16S rRNA gene sequencing
    Maria Luiza Soares de Souza


  • Chair:
    Milena Botelho Pereira Soares, Senai CIMATEC / Fiocruz-Bahia*


    Presentations:
    RNA vacines platform
    Patricia Neves, Bio-Manguinhos / Fiocruz*

    RNAi therapeutics: moving from the research to a reality
    Jing-Tao Wu, Alnylam Pharmaceuticals*

    Helper Lipids: Impact on Expression, Immunogenicity, and Stability of Self-Amplifying RNA Lipid Nanoparticle Vaccines
    Beatriz Dias Barbieri, Imperial College London*
    Biofármacos
    Vacinas

  • Lunch box


    Poster pitch 43: ORT-12 – Influence of carbonic anhydrase IX and Cyclooxygenase-2 on Immune Checkpoint
    Renata Schmieder Pivetta

    Poster pitch 44: BIO-05 – Development of a peptide mapping protocol with post-translational modifications detection for the recombinant human erythropoietin by LC-MS/MS-based proteomics
    Jose Roberto Aparecido dos Santos-Pinto

    Poster pitch 45: BIO-10 – Consensus serine protease toxin design as antigen and cross-immunization combined strategy for generation of broadly binding antibodies
    Daniel Alexandre de Souza

    Poster pitch 46: IVD-11 – Comparison of two forms of a multi-epitope protein, DxCruziV3, for the development of an ELISA-based diagnostic test for Chagas disease
    Juliana Toledo Nascimento

    Poster pitch 47: ORT-19 – Neurofilament light chain as biomarkers for therapeutic monitoring in patients with Relapsing remitting Multiple Sclerosis
    Larissa Araujo Duarte

    Poster pitch 48: ORT-03 – Humoral immunological status after heterologous boosts with COVID-19 vaccines: neutralizing antibodies and IgG avidity against ancestral or variants of SARS-CoV-2
    Brenda de Moura Dias

    Poster pitch 49: ORT-14 – Neutralizing antibody Levels against Wuhan Strain and the Omicron Variant of SARS-CoV-2 in patients with COVID-19 Disease
    Ingrid Siciliano Horbach

    Poster pitch 50: BIO-04 – Surveillance of influenza viruses with reduced susceptibility to antivirals in Brazil during the COVID-19 pandemic
    Thiago das Chagas Sousa


  • Chair:
    Danielly Magalhães, Fiocruz/CRIS




    Presentations:
    Government agenda
    Alexandre Ghisleni, MoH/AISA

    Engagement and innovation agenda
    Luciana Servo, IPEA – T20*


  • Chair:
    Akira Homma, Bio-Manguinhos / Fiocruz*


    Keynote speaker:
    Rino Rappuoli, Biotecnopolo di Siena Foundation *
    Vacinas

  • Chair:
    Maurício Zuma, Bio-Manguinhos/Fiocruz*


    Keynote speaker:
    Sarah Gilbert, Oxford University*

    Clinical trials of the coronavírus vaccine in Brazil
    Sue Ann Costa Clemmens, Oxford Latam*
    Vacinas


Conheça alguns palestrantes do 6th ISI - 2022

Patrocinadores

Realização